author-photo

Rajesh Malik

Research Triangle Park

20

Papers

359

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

1671PTrilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

2017 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (64)
P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results: Topic: Drug Treatment Alone and in Combination with Radiotherapy

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth: Topic: Clinical Trials

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)